MedTech Innovator

Samay is a developer of an innovative AI-enabled wearable device focused on remote respiratory health management. The company addresses the growing need for effective chronic obstructive pulmonary disease (COPD) diagnostics and management, projected to incur significant healthcare costs in the coming years. Their patented chest patches provide passive monitoring of lung function, achieving 90% accuracy in COPD diagnosis and 83% accuracy in detecting exacerbation biomarkers. The device continuously tracks vital respiratory metrics, including pulmonary volumes, heart rates, and breathing sounds for two weeks, offering users valuable insights to optimize their respiratory health. Additionally, Samay is creating an AI-assisted management platform that supports patients and healthcare providers throughout the care continuum, enhancing personalized care from the comfort of home.

APrevent Medical Inc. is a medical device company founded in 2014 and headquartered in Taipei, Taiwan, with an additional office in Austria. The company specializes in developing therapeutic medical devices aimed at enhancing the quality of life for patients suffering from speech disorders. APrevent Medical focuses on innovative solutions, including a long-term implant system and a speech conversion platform, designed to provide minimally invasive treatments and support for voice and communication issues. By integrating advanced technologies, the company aims to offer effective interventions that enable patients to improve their speech capabilities and overall communication.

INIA Biosciences is a developer of innovative medical devices that leverage sound wave technology to create non-invasive, home-administered systems for managing chronic inflammatory diseases. The company focuses on a closed-loop monitoring system designed to treat and prevent organ failure by integrating biomarker monitoring with an ultrasound stimulator. This approach aims to reduce inflammation linked to transplant rejection rates and minimize reliance on immunosuppressant drugs. By providing novel diagnostic sensing capabilities, INIA Biosciences enables physicians to better manage chronic diseases and improve patient outcomes.

Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices aimed at addressing challenges in infectious disease testing, particularly for influenza. The company manufactures microchip-based devices that allow users to quickly and accurately diagnose illnesses. By providing early diagnosis solutions, Nanotis supports medical professionals in practical healthcare settings, thereby enhancing the efficiency of healthcare delivery and improving patient outcomes.

Samay is a developer of an innovative AI-enabled wearable device focused on remote respiratory health management. The company addresses the growing need for effective chronic obstructive pulmonary disease (COPD) diagnostics and management, projected to incur significant healthcare costs in the coming years. Their patented chest patches provide passive monitoring of lung function, achieving 90% accuracy in COPD diagnosis and 83% accuracy in detecting exacerbation biomarkers. The device continuously tracks vital respiratory metrics, including pulmonary volumes, heart rates, and breathing sounds for two weeks, offering users valuable insights to optimize their respiratory health. Additionally, Samay is creating an AI-assisted management platform that supports patients and healthcare providers throughout the care continuum, enhancing personalized care from the comfort of home.

FemTherapeutics Inc. is a Montreal-based medical device company focused on personalizing therapeutics in women’s health. The company has developed an artificial intelligence platform that utilizes patient data and three-dimensional printing technology to create customizable gynecological prosthetics, specifically designed for the management of Pelvic Floor Disorders. Their innovative approach aims to improve the clinical outcomes for women suffering from conditions such as pelvic organ prolapse and stress urinary incontinence, providing non-invasive solutions that enhance quality of life through effective symptom relief. FemTherapeutics’ commitment to leveraging advanced technology positions it at the forefront of women's health innovation.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Flow Medical specializes in the development of multi-function catheters aimed at diagnosing and treating venous thromboembolic illnesses, including pulmonary embolism. The company's innovative platform enhances clot visualization and allows for the targeted delivery of clot-dissolving medication directly to the site of blockage. Additionally, it provides real-time monitoring of treatment progress, enabling clinicians to tailor therapy to the specific needs of each patient. Through its advanced catheter technology, Flow Medical seeks to improve patient outcomes in the management of thrombotic conditions.

NanoBioFAB is a company based in Frederick, Maryland, specializing in the development of wearable, smart healthcare and medical devices utilizing nanotechnology. Founded in 2015, the company produces innovative products such as iNose, a device that allows individuals to detect, track, and monitor their body’s skin vapor-print. This device connects wirelessly to mobile phones, enabling users to track their fat burning rate, assess the effectiveness of their exercise routines, and observe the long-term effects of their dietary choices on metabolic rates. Additionally, NanoBioFAB offers nanoprinting technology and artificial intelligence sensors aimed at enhancing telemedicine and personalized healthcare solutions. The company is dedicated to making advanced healthcare accessible and affordable for both people and pets.

Founded in 2019, Promedius is a company dedicated to transforming the approach to aging through innovative technologies aimed at the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. Promedius has developed PROS® CXR:OSTEO, a pioneering screening solution that utilizes chest X-ray images combined with artificial intelligence to identify individuals at risk for osteoporosis. This technology is designed to prevent severe fractures among the elderly population, facilitating timely intervention and enhancing the overall quality of life. By harnessing AI in medical imaging, Promedius aims to support healthcare professionals in their efforts to improve patient outcomes and extend healthy lifespans.

FibriCheck is a medically certified application designed for the screening and monitoring of irregular heart rhythms, including atrial fibrillation. Functioning as a software-only solution, it allows users to measure their cardiac rhythm simply by placing a finger on their smartphone camera, making it accessible for use anytime and anywhere. The application automatically shares the collected data with medical professionals, facilitating quicker diagnoses and the development of appropriate treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, enabling it to leverage everyday smartphones and wearables. This innovative approach aims to enhance cardiovascular care by accurately detecting and tracking heart rhythm issues, while also helping individuals manage conditions such as high blood pressure and heart failure through user-friendly tools and customizable health plans.

Ortho-tag is a developer of innovative in-vivo platforms that facilitate the connection between digital health applications and implanted biosensors within the human body. The company's technologies focus on enhancing wireless communication with medical devices through proprietary transcutaneous volume conduction. This enables real-time data exchange, in-vivo storage, and the integration of nanodiagnostic and therapeutic functions in smart medical implants. By providing a comprehensive system for wireless communication and data management, Ortho-tag supports medical device developers in advancing the capabilities of healthcare technology.

AccurKardia is an ECG-led diagnostics software company dedicated to enhancing the utility of ECG data as a diagnostic tool and biomarker to improve patient outcomes globally. The company specializes in cloud-based diagnostic solutions, including AccurECG™, an FDA-cleared software that provides fully automated, near real-time ECG interpretation. Additionally, AccurKardia developed AK+ Guard™, an AI-driven solution designed to detect hyperkalemia using Lead I ECG data, which aids patients with chronic kidney disease and end-stage renal disease in identifying dangerously high potassium levels at an earlier stage; this product has received FDA Breakthrough Device Designation. The company's aortic stenosis detection model, AK-AVS™, also received similar recognition. AccurKardia participated in the 2024 Cohort of MedTech Innovator and was selected for the inaugural American Heart Association's Heart and Brain Health Accelerator track, further emphasizing its commitment to advancing cardiac diagnostics and monitoring.

Invicta Medical, Inc. is a medical technology company that specializes in developing innovative therapies for sleep apnea and snoring. Founded in 2013 and headquartered in Portola Valley, California, the company has created a wearable device that utilizes neurostimulation to detect and treat disturbed breathing. This device aims to overcome the limitations of traditional therapies, which are often costly, invasive, and have low compliance rates among patients. By offering a smart, comfortable, and cost-effective solution, Invicta Medical seeks to provide effective treatment options for individuals suffering from sleep disorders.

Qritive is a technology company that offers an artificial intelligence-powered diagnostic platform aimed at enhancing the accuracy and efficiency of cancer diagnoses. By utilizing advanced AI and natural language processing, Qritive's solution enables medical professionals to analyze microscopy images alongside patients' medical histories. This innovative approach allows hospitals to streamline their diagnostic processes, ultimately reducing costs and improving patient outcomes. With the rising incidence of cancer, Qritive addresses a critical need in the healthcare sector, equipping doctors with modern tools to aid in timely and precise cancer detection.

iCE Neurosystems is a developer of an advanced neuromonitoring platform aimed at enhancing the diagnosis and treatment of brain injuries. The company combines innovative devices, cutting-edge software, and big-data analytics to deliver real-time insights into brain health. This integration enables healthcare professionals to receive early warnings and guide treatment for patients suffering from brain injuries, particularly in critical care settings. By providing revolutionary insights, iCE Neurosystems enhances the ability of doctors and nurses to diagnose and prevent brain injuries more effectively.

VinBrain is a healthcare technology company that specializes in artificial intelligence applications within the medical field, particularly in medical imaging and diagnostics. The company offers DrAidTM Teleradiology, a remote medical imaging solution that facilitates the connection of resources and expertise between hospitals, ensuring patients receive quality diagnostic imaging services anytime and anywhere. VinBrain's platform enhances patient outcomes by identifying and distinguishing various types of cancerous cells and tissues, analyzing medical histories to pinpoint potential risk factors, and automatically generating reports based on healthcare data. Utilizing computer vision and generative AI, the company streamlines radiologists' workflows, providing healthcare providers with valuable insights to improve diagnosis, treatment, and overall patient care, while also enhancing operational efficiency.

Prevencio is a biotechnology company focused on developing innovative multi-proteomic biomarkers aimed at transforming blood tests for cardiovascular disease. Utilizing artificial intelligence, the company's biomarkers analyze established clinical data sets to create novel, multi-protein tests that are algorithmically scored. These tests enable clinicians to evaluate the effects of medications before and after administration, specifically concerning a composite risk of heart attack, stroke, and cardiac death. By leveraging advanced technology in biomarker development, Prevencio seeks to enhance the accuracy and effectiveness of cardiovascular diagnostics.

Craif Inc., formerly known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for the early detection of cancer through non-invasive urine tests. The company focuses on utilizing MicroRNA, an early cancer biomarker, which facilitates the identification of cancer at its initial stages, thereby significantly increasing survival rates and improving patient prognosis. Craif aims to address the challenges of traditional cancer diagnosis methods, which can be painful and often lack the necessary accuracy for early detection. By leveraging exosome-based liquid biopsy tests and ribonucleic acid technology, Craif provides research institutions with high sensitivity and specificity in distinguishing between cancerous and non-cancerous samples, positioning itself as a pioneer in the field of early cancer diagnosis.

NIRAMAI Health Analytix Private Limited is a Bengaluru-based company that specializes in cancer screening through its innovative software, Thermalytix, which leverages machine intelligence to analyze thermography images. Founded in 2016, the company offers a range of hardware-software solutions tailored for various users, including a compact screening device for specialty hospitals, a handheld device for independent medical practitioners, and a portable solution designed for large-scale screenings. NIRAMAI's technology enables early detection of breast cancer, identifying tumors significantly smaller than those detectable by traditional methods. Their approach is non-contact, painless, and free of radiation, making it a low-cost and accessible option for women of all age groups to undergo frequent screenings without adverse effects. By facilitating early diagnosis, NIRAMAI aims to improve survival rates and enhance the quality of cancer care.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

DiaMonTech AG is a Berlin-based medical technology company founded in 2015, specializing in the design, development, and commercialization of non-invasive blood glucose monitoring devices. Utilizing proprietary laser-based photo-thermal detection technology, DiaMonTech offers solutions that allow diabetes patients to measure their glucose levels without the pain of finger pricking or the need for blood samples. The company has developed several innovative products, including D-BASE, a shoebox-sized device for conducting human trials, D-pocket, a portable device for frequent glucose level tracking, and D-BAND, a wearable device that continuously monitors blood glucose levels. Through these advancements, DiaMonTech aims to improve the quality of life for individuals managing diabetes.

Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.

Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.

StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.

IFPx is a company focused on developing innovative monitoring technology for patients with chronic illnesses, beginning with heart failure. The company has created a patient monitoring device that directly analyzes fluid buildup, which is crucial for managing such conditions. By utilizing interstitial fluid pressure sensors, IFPx aims to enhance the monitoring capabilities available to healthcare professionals, thereby improving patient outcomes in heart failure management. The company's technology represents a significant advancement in the approach to chronic illness treatment, emphasizing the importance of real-time data in patient care.

Biotome is a biotechnology research firm focused on developing advanced antibody diagnostic tests. The company specializes in identifying markers that indicate a high risk of stomach cancer, aiming to provide more precise and detailed disease information compared to current screening methods. By leveraging next-generation technology and precision immunology, Biotome's tests are designed to enhance the ability of medical professionals to treat patients effectively.

StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.

AMI Co., Ltd is a Japanese company based in Minamata-shi, established in 2015, that specializes in the manufacturing of medical equipment, primarily stethoscopes. In addition to producing medical devices, AMI is involved in healthcare consulting, offering services such as hospital management and clinical research. The company is also focused on developing telehealth solutions, including a telemedicine system that enhances remote medical consultations. Among its innovations is a video chat platform designed for remote auscultation, which allows for the separate transmission of heart sounds as both audible and visible data, thereby improving patient access to medical services through telemedicine initiatives.

SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

DasiSimulations is a company that specializes in providing innovative simulations aimed at enhancing pre-operative preparation for patients with heart disease, particularly those suffering from Structural Heart Disease. Founded in 2019 by Teri Anderson-Sirset and Dr. Dasi, and headquartered in Dublin, Ohio, DasiSimulations focuses on improving patient outcomes and reducing healthcare costs through advanced individualized computational predictive modeling. Utilizing artificial intelligence and proprietary algorithms, the company's technology platform empowers medical professionals to make more informed decisions during transcatheter aortic valve replacement procedures.

Senseye, Inc. is a Los Angeles-based company founded in 2015 that specializes in developing innovative smart contact lenses capable of non-invasively recording and analyzing information from users. These contact lenses are designed to infer human emotions, thoughts, and health states, thereby assisting in various applications such as market research, disease diagnosis, and early detection of medical conditions like strokes and heart attacks. By utilizing novel measurements of ocular physiology, Senseye aims to quantify cognitive abilities and psychological well-being, providing valuable insights into vital signs, attention, cognitive load, and fatigue. The company is committed to advancing technology that enhances emotional responses and mental health diagnostics, enabling clinicians to offer personalized care and effectively track patient outcomes over time.

Xcision Medical Systems, LLC is a medical technology company focused on developing innovative stereotactic radiotherapy solutions aimed at enhancing cancer treatment. The company specializes in manufacturing radiosurgery devices specifically designed for breast cancer treatment. Its technology utilizes stereotactic gamma irradiation, allowing for a complete course of radiation therapy to be delivered in a single, noninvasive session. This approach significantly reduces the duration of treatment compared to traditional methods, while minimizing radiation exposure to surrounding healthy tissues, including the lungs and heart. As a result, patients can resume their daily activities more quickly and with less discomfort, ultimately improving their quality of life. Additionally, Xcision's advancements enable healthcare professionals to enhance the overall quality of cancer care they provide.

Sonavi Labs, Inc. is a medical device and software company based in Baltimore, Maryland, founded in 2017. The company specializes in developing advanced technologies that analyze body sounds to aid in the diagnosis of respiratory diseases. By utilizing artificial intelligence, Sonavi Labs creates innovative products that enhance the capabilities of healthcare providers and improve patient experiences. Its devices are designed to detect and manage respiratory conditions by listening to bodily sounds and identifying abnormalities, thereby enabling healthcare professionals to monitor, diagnose, and potentially predict diseases effectively. Through its focus on modern medical solutions, Sonavi Labs aims to transform the landscape of respiratory health monitoring.

Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.

EchoPixel, Inc. is a medical visualization software company that specializes in three-dimensional imaging technology. Established in 2012 and based in California, EchoPixel develops advanced solutions that allow medical professionals to interact with patient-specific organs and tissues in a virtual reality environment. Its flagship product, the True 3D Viewer, provides a real-time, interactive platform for evaluating and dissecting anatomical structures, enhancing the diagnostic process. Additionally, the company offers the True 3D Medical Education Viewer, which aids medical students in understanding three-dimensional anatomy through computer tomography and magnetic resonance images. EchoPixel also focuses on non-invasive diagnostic tools, including a colon cancer screening solution that utilizes computed tomography images to create a detailed 3D model of the colon, allowing healthcare providers to detect polyps and other abnormalities effectively.

3EO Health is dedicated to creating a society where individuals are empowered to enhance their health across various aspects of life, including patient care, community engagement, and personal well-being. The company develops innovative molecular point-of-care platforms that utilize advanced technology to significantly reduce costs while improving access to impactful diagnostic tools. By leveraging its proprietary 3TR technology, 3EO Health offers molecular performance that is more affordable than existing options, ensuring equitable access to high-quality health solutions for both physicians and consumers. Its mission extends beyond traditional healthcare settings, aiming to integrate health optimization into communities, workplaces, and homes, thus fostering an environment where individuals can thrive.

CORIT Medical LLC is a commercial medical device company based in McLean, Virginia, specializing in a Class I single-use surgical device designed to enhance breathing. The company's patented device is intended for the established Ear, Nose & Throat (ENT) procedure of inferior turbinate reduction, which addresses obstructed breathing—a condition affecting over 50 million people in the United States. Each year, approximately 1 million of these procedures are performed, and the device offers a more efficient and durable solution compared to competing technologies, which may see patients return to pre-treatment obstruction levels within six months. CORIT's hand-powered device does not require expensive equipment, allowing ENT specialists to perform the procedure in their offices and complete it in a fraction of the time typically needed in an operating room, thus increasing patient acceptance and reimbursement potential.

4th Dimension EMR is a software development company specializing in electronic health record (EHR) solutions for healthcare practitioners. The company offers a cloud-based platform that facilitates practice management and the administration of patient information. Its software aids in documentation and streamlines scheduling, allowing clients to efficiently manage their workflows. By providing tools that enable access to medical records from any location, 4th Dimension EMR supports healthcare providers in enhancing their operational efficiency and delivering quality patient care.

Thermidas, a Finnish health technology company, specializes in developing and advancing infrared thermal imaging for diagnostic purposes. Its core product is thermal imaging software, designed to support screening, early diagnostics, and evaluation of treatment effectiveness. The technology enables swift and simple detection of asymmetric body temperature, which can indicate underlying health issues like inflammation, circulatory problems, and potential ulcers. This allows university hospitals and experienced clinicians to identify and diagnose conditions at earlier stages than traditional methods.

Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.

Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.

Covellus is a medical device company focused on developing innovative platform technology for catheters used in minimally invasive surgeries. The company specializes in manufacturing vascular catheter devices and modular catheter systems, which allow physicians to customize existing devices to meet the specific needs of individual patients. By enhancing the versatility and adaptability of medical devices, Covellus aims to improve treatment outcomes in various medical procedures.

Prana Thoracic, Inc., based in Houston, is a medical device startup focused on developing innovative solutions for the early intervention of lung cancer, the leading cause of cancer-related deaths in the United States. The company aims to address the critical challenges in lung cancer screening and diagnosis, where only a small percentage of cases are detected at an early stage. Prana Thoracic's advanced electrosurgical instrument utilizes bipolar radiofrequency energy to perform minimally invasive procedures, enabling physicians to capture and diagnose small, hard-to-reach lung nodules while reducing the risk of complications. By enhancing the tools available for surgical oncology in lung cancer, Prana Thoracic seeks to improve patient outcomes and capitalize on recent advancements in screening guidelines, ensuring early intervention opportunities are not missed.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

Manufacturers of innovative medical devices intended to incorporate sensors, both therapeutic and diagnostic, to help people overcome musculoskeletal problems. The company provides NMES (Neuromuscular Electrical Stimulation) devices that invoke neuroplasticity for optimal outcomes and offers medical devices for physical therapy and rehabilitation, thereby enabling patients to regain and improve their range of motion and function.

Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence. The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.

LiveMetric is a medical device company focused on developing innovative, non-invasive sensing and deep data analytics solutions aimed at improving the management of hypertension and cardiovascular diseases. The company offers a wearable, cuff-free device for blood pressure monitoring that is FDA-cleared and validated for accuracy against traditional arterial line methods. This technology provides high-fidelity arterial pressure waveforms and continuous tracking of vital signs, allowing for real-time feedback and analysis for patients, physicians, and healthcare providers. By delivering personalized data and detailed activity mapping, LiveMetric aims to empower individuals, payors, self-insured employers, and healthcare providers, ultimately enhancing the care and quality of life for over one billion people worldwide affected by these conditions.

CARI Health is a digital health company based in San Diego, California, that specializes in developing remote medication monitors. Founded in 2015 and incorporated in 2021, CARI Health's innovative monitors utilize wireless sensors worn on the patient's skin to continuously transmit real-time data about medication levels to the cloud. This technology enables clinicians to safely prescribe, dose, and monitor adherence to life-saving medications, thereby enhancing patient care and treatment outcomes.

Garwood Medical Devices, LLC is a Buffalo, New York-based company that develops and manufactures innovative medical devices aimed at combating infections related to prosthetic implants and wound healing. The company specializes in BioPrax, a minimally invasive device designed to target and eliminate biofilm infections on prosthetic knee implants during early intervention procedures. By effectively addressing infection-causing bacteria without necessitating follow-up surgeries, Garwood Medical Devices enables healthcare practitioners to improve treatment outcomes and help patients retain their implants. Originally founded as Enermed, LLC in 2014, the company rebranded to its current name in December 2015, reflecting its commitment to advancing medical technology in the field of infection management.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients. The company's innovative device employs a closed-loop approach combined with machine learning algorithms to deliver personalized peripheral neuromodulation. This technology mediates a cardiovascular antiarrhythmic response, enabling users to effectively reduce the burden of atrial fibrillation and its precursors, such as premature atrial contractions. As a result, CardiaCare’s solution offers users rapid clinical and symptomatic relief, providing a valuable tool for managing their condition in a home setting.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

SafeBeat Rx is a technology company specializing in advanced electrocardiogram solutions aimed at enhancing cardiac care. The company has developed software that facilitates remote patient monitoring, continuous telemetry, and event monitoring, significantly reducing the need for prolonged hospital stays for cardiac patients. By leveraging automated artificial intelligence, SafeBeat Rx's technology allows for safe medication initiation for arrhythmia patients while enabling effective monitoring of cardiac implantable electronic devices. This innovative approach expands access to cardiac care, allowing patients to receive essential services from the comfort of their homes.

Augment Health is a company focused on developing noninvasive medical devices and artificial intelligence algorithms to enhance the management of bladder dysfunction, particularly for the 7 million patients affected by neurologic disease or injury. The company's innovative technology allows for monitoring urine levels through a device that can be attached to catheters, providing timely notifications to users or care providers when the catheter reaches capacity. This approach aims to shift bladder diagnostics from clinical settings to patients' homes, addressing the high rate of inconclusive test results associated with traditional in-clinic diagnostics. By enabling better bladder health management, Augment Health seeks to prevent complications such as bladder muscle atrophy, ultimately improving the quality of life for patients.

SymPhysis Medical is focused on developing innovative medical technologies aimed at treating chronic diseases, with a particular emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, is a therapeutic device designed for the home management of malignant pleural effusions (MPE), a common complication in late-stage cancer patients. MPE can lead to severe symptoms such as shortness of breath and chest pain, affecting approximately 15% of cancer patients. The releaze device effectively drains excess fluid from the pleural space, utilizing an active component to improve removal efficiency. This technology not only alleviates debilitating symptoms but also makes indwelling pleural catheter treatments more accessible for patients, significantly contributing to their overall well-being.

DermaSensor, Inc. is a Miami-based company that specializes in developing innovative technology for skin cancer evaluation. Founded in 2009, the company has created a handheld device that employs artificial intelligence, machine learning, and elastic scattering spectroscopy to assess skin lesions for potential cancer. This device enables both physicians and consumers to perform skin checks in various settings, including clinics and at home. By providing an efficient and affordable solution for early skin cancer detection, DermaSensor aims to improve access to vital healthcare services and reduce the costs associated with skin cancer diagnosis. The technology not only identifies cancerous cells but also sends alerts when such cells are detected, facilitating timely intervention.

ConKay Medical Systems is an early-stage medical device company focused on creating innovative solutions for treating valvular regurgitation in patients experiencing progressive heart failure. The company has developed a device that utilizes annular repair technology to address the primary cause of functional regurgitation, preserving the integrity of healthy leaflets to ensure they function as intended. By advancing cardiovascular care, ConKay Medical Systems aims to improve treatment outcomes for patients with this serious condition.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

CloudMedx Inc. is a software development company that specializes in artificial intelligence solutions aimed at extracting critical clinical insights from electronic health records. Founded in 2014 and based in Palo Alto, California, the company transforms raw healthcare data into actionable insights that enhance clinical operations, documentation, and patient care. Its platform leverages population health history to improve clinical, treatment, and diagnostic outcomes, while also notifying physicians when care is necessary. CloudMedx provides patient-centric tools that facilitate engagement, risk stratification, and actionable insights, serving a range of healthcare entities including managed care organizations, accountable care organizations, physician-led organizations, emergency rooms, urgent care facilities, and lab testing sites. The company’s mission is to unify healthcare systems, enabling better collaboration among providers, payers, and patients, ultimately improving the accuracy and quality of care delivered.

Corveus Medical is a medical device company focused on innovative solutions for preventing heart failure. The company is developing a neuromodulation device designed to perform nerve ablation through a catheter-based approach. This minimally invasive technology aims to effectively target and access specific tissues, offering a novel treatment option for heart failure. By addressing both the clinical and economic challenges associated with this condition, Corveus Medical seeks to improve patient outcomes and enhance the overall management of heart failure.

Phagenesis Limited is a medical device company based in Manchester, United Kingdom, founded in 2007. It focuses on developing innovative technology to treat dysphagia, a condition often associated with stroke and brain injuries that impairs safe swallowing. The company's flagship product, Phagenyx, consists of a base station that delivers targeted electrical stimulations to patients while recording and storing their information, and a catheter that is introduced through the nose to stimulate the pharynx. This approach leverages the brain’s neuroplasticity, enabling patients to relearn essential swallowing functions that may have been lost due to brain damage. Phagenesis aims to improve the recovery process for stroke patients in acute care settings by utilizing a method developed by Prof. Shaheen Hamdy of the University of Manchester, which has been validated through publication in reputable scientific and medical journals.

Tricog Health is a company that specializes in cardiac diagnostic tools aimed at addressing cardiovascular conditions through real-time identification and accurate analysis. Utilizing medical-grade artificial intelligence, Tricog improves cardiac care by bridging gaps in infrastructure, expertise, and efficiency within healthcare systems. The company offers virtual diagnostic tools and services that empower healthcare providers to make timely and precise diagnoses, ultimately enhancing patient outcomes. Tricog's innovative medical device facilitates real-time reporting and analysis of electrocardiography results without the need for additional hardware, ensuring early detection of potentially life-threatening cardiac events.

Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions. The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions. Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.

PyrAmes is a healthcare technology company that has created an innovative, paper-thin, flexible device for non-invasive blood pressure monitoring. This ultra low-power device is designed to deliver continuous and accurate blood pressure measurements wirelessly, making it suitable for patients of all ages, from newborns to seniors. PyrAmes aims to transform healthcare delivery by providing a platform that enables healthcare providers to conduct pain-free blood pressure monitoring, particularly benefiting vulnerable populations such as neonates.

HD Medical is a developer of innovative medical technology focused on cardiovascular health. The company has created a visual stethoscope that integrates electrocardiogram (ECG) capabilities, allowing healthcare professionals to visualize heart sounds and cardiac waveforms in real time at the point of care. This advanced device not only displays heart waveforms but also enables the recording of results, facilitating early detection and management of cardiovascular diseases. By providing tools for patient diagnosis and treatment, HD Medical aims to enhance the effectiveness of cardiovascular disease management.

Sepsis Scout is a developer of a wearable patch designed to predict the onset of sepsis in high-risk patients in home care settings. Utilizing proprietary deep learning technology, the device aims to detect sepsis more accurately than current standards of care. By enabling patients to manage chronic illnesses effectively, Sepsis Scout's solution helps individuals stay out of the hospital and alleviates the fear and uncertainty associated with serious health conditions. The company's focus on artificial intelligence and wearables positions it at the forefront of innovative healthcare solutions.

Avisi Technologies Inc. is a Philadelphia-based company founded in 2017 that specializes in developing innovative solutions for glaucoma treatment. Its primary product, VisiPlate, is a next-generation, nanotechnology-enabled aqueous shunt designed to prevent blindness caused by glaucoma. Through its advanced technology, Avisi Technologies aims to enhance the effectiveness of glaucoma management and improve patient outcomes.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, specializing in AI-powered medical imaging solutions. Founded in 2017, the company develops innovative software products such as SubtleMR and SubtlePET, which are designed to enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These products utilize proprietary deep learning algorithms to reduce image noise and improve sharpness, thereby increasing efficiency and safety in clinical workflows. Subtle Medical's technology is FDA cleared and CE marked, and it operates on a vendor-agnostic AI infrastructure that integrates seamlessly with existing imaging systems. The company's mission is to enhance the quality, value, and accessibility of medical imaging by lowering costs, reducing imaging time, and minimizing radiation and contrast doses for patients.

ZKR Orthopedics is focused on developing innovative medical devices and procedures to treat chronic knee pain, particularly caused by Condromalacia Patellae, a condition characterized by the degeneration of cartilage and inflammation beneath the kneecap. Millions of individuals suffer from this ailment, often delaying medical treatment due to the traditionally invasive nature of available solutions, which typically involve major surgery. ZKR's approach offers a minimally invasive option that aims to alleviate pain, restore mobility, and potentially reduce the need for knee replacement surgery. The company, founded by Dr. Jeffrey Halbrecht, has successfully developed prototypes and holds multiple patents for its technology. Currently, ZKR is seeking capital to fund product trials, further advancing its mission to improve patient outcomes in orthopedic care.

Respirix, Inc. is a United States-based company focused on developing advanced analysis sensors for monitoring breath exhalation and cardiogenic oscillations. The company offers digital health software and hardware designed to provide proprietary insights into the pulmonary vasculature in a non-invasive manner. Respirix's product pipeline targets both at-home monitoring and critical care applications, specifically in areas such as heart failure and hemodynamics. Its innovative approach aims to enhance patient care by delivering precise and actionable data related to respiratory and cardiovascular health.

InVera Medical is focused on developing innovative medical devices aimed at treating varicose veins and venous ulcers. The company is creating BioVena™, a less invasive and pain-free treatment option that utilizes the body's natural biological response to address venous diseases. This proprietary technology positions InVera Medical to significantly improve patient outcomes by providing a safer and more effective alternative to existing treatment methods. With only a small fraction of the 120 million individuals suffering from venous disease receiving adequate endovenous treatment annually, InVera Medical seeks to broaden access to effective care for a population largely underserved by current solutions. The company’s advancements are particularly crucial given the high annual costs associated with venous ulcers, which amount to approximately $33 billion for insurers in the US and EU. By targeting the full spectrum of venous disease, InVera Medical aims to enhance the quality of life for patients who have long been limited to ineffective compression bandaging.

CloudCath is a company that specializes in developing a sensor-enabled digital platform tailored for patients undergoing peritoneal dialysis. The platform integrates Internet of Things-based sensing hardware with a continuous monitoring system, allowing for the early detection of complications associated with catheter-based treatments. This innovative approach not only enhances patient care by enabling healthcare providers to monitor patients remotely during their home treatments but also aims to reduce the frequency of in-person visits required each month. By focusing on early complication detection, CloudCath seeks to improve patient outcomes in the management of dialysis therapy.

AMB Surgical is a developer of innovative medical devices aimed at treating pediatric deformities, particularly scoliosis. The company has created an electro-mechanical smart automated growing rod known as "FLYTE," which allows for precise and frequent non-surgical adjustments through sensor feedback. This technology enhances the capabilities of surgeons in managing complex cases involving pediatric scoliosis, dynamic external fixation for deformity correction, and applications related to long bone lengthening. By providing a solution that minimizes the need for invasive surgical procedures, AMB Surgical aims to improve treatment outcomes for children facing these conditions.

Conavi Medical specializes in intravascular and intracardiac imaging technology aimed at facilitating minimally invasive medical procedures. The company has developed a catheter-based ultrasound system that generates both 2-D and 3-D ultrasound images of cardiac anatomy surrounding the catheter's tip. This innovative technology assists medical professionals in performing complex cardiovascular procedures, such as ablations, by providing precise visualization of targeted areas within the heart. Through its advanced imaging capabilities, Conavi Medical enhances the effectiveness and safety of interventions in the cardiovascular field.

Impleo Medical is a company focused on developing minimally invasive medical devices specifically for the treatment of gastroesophageal reflux disease (GERD). It has created an outpatient injection therapy platform that allows for a one-time procedure under sedation, providing durable relief from acid reflux. This innovative approach addresses a significant gap in treatment options, lying between traditional medications and surgical interventions. By enabling physicians to effectively prevent the flow of gastric acid into the esophagus, Impleo Medical aims to enhance patient outcomes and improve quality of life for those suffering from GERD.

Spire Health, established in 2013 and headquartered in San Francisco, specializes in developing health-tracking devices and remote patient monitoring solutions. The company's core product is a wearable device that senses physical movement, position, and breathing patterns, providing insights into daily activities and mental state through a mobile application. Spire Health focuses on chronic respiratory disease management, offering solutions for conditions such as COPD, congestive heart failure, asthma, and sleep disorders. Their mission is to empower patients and physicians with useful, actionable data by harnessing the power of algorithms and sensors, thereby improving health outcomes.

ODS Medical Inc. is a Montreal-based medical device company established in 2015, specializing in the design and manufacture of advanced diagnostic tools for cancer detection. The company's flagship product is an exclusive Raman spectroscopy system that enables real-time identification of tissue abnormalities across various clinical settings. By integrating innovative optical probes with sophisticated software powered by machine learning algorithms, ODS Medical aims to enhance the capabilities of physicians, allowing for critical decision-making with high sensitivity, specificity, and accuracy. Through its commitment to developing and commercializing cutting-edge technology, ODS Medical strives to revolutionize the diagnostic landscape in oncology.

PhotoniCare, Inc. is a medical device company based in Champaign, Illinois, founded in 2013. The company specializes in developing innovative diagnostic tools for middle ear infections, particularly through its flagship product, the TOMi Scope. This handheld device utilizes advanced light-based technology, specifically near-infrared light waves, to provide 3D visualization of the middle ear beyond the eardrum. By enabling physicians to directly and harmlessly visualize the middle ear, PhotoniCare's technology allows for rapid assessment of middle ear conditions, assisting in determining the appropriate treatment, whether it be antibiotics or surgical intervention. The company's imaging platform also presents potential for future growth beyond otology.

CU-BX is a health analytics platform focused on enhancing driver safety and comfort through advanced monitoring solutions. The company specializes in providing high-accuracy measurements of various health parameters, including fatigue, stress, heart rate, and respiratory rate. Its patented technology ensures reliable performance across diverse road and lighting conditions and is adaptable to various clothing and accessories. CU-BX collaborates with major automotive stakeholders, including original equipment manufacturers and suppliers, to develop driver monitoring systems and aftermarket solutions. By integrating sophisticated sensors and dashcam data, CU-BX aims to improve in-cabin comfort and promote safer driving practices, making it a key player in the automotive health analytics sector.

Darmiyan, Inc. is a biotechnology company focused on early detection and monitoring of neurodegenerative diseases, including Alzheimer's disease. Founded in 2014 and based in San Francisco, California, the company has developed a proprietary diagnostic software platform known as BrainSee. This Software as a Service (SaaS) platform utilizes standard clinical brain MRI scans and basic cognitive tests to generate detailed brain maps and quantifications of neurodegeneration in each voxel. BrainSee provides a summary score reflecting an individual's brain health and the likelihood of future cognitive decline, allowing for diagnosis at early stages when treatment options are most effective. The technology, referred to as The Virtual Microscope, employs advanced medical image analysis and artificial intelligence, underpinned by over 40 years of neuroscience research. It has undergone successful third-party validation in the United States and Canada, demonstrating high accuracy and consistency in predicting mild cognitive impairment, and has received endorsements from notable figures in the medical community.

Deton is a company dedicated to advancing the understanding and treatment of lung diseases through innovative diagnostic technology. It specializes in the development of Aerosol Biopsy, a method that provides comprehensive and timely information on lung health. This technology is designed to collect samples from the lower respiratory tract, facilitating the detection of lower respiratory tract infections. By meticulously preserving bacterial elements, Deton's approach allows researchers to study the growth of fungal and bacterial microbes over time. This capability enhances the diagnosis and detection of lung disorders, ultimately contributing to more effective treatment options for patients suffering from respiratory conditions.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

PharmaJet, Inc. is a company that develops and markets innovative needle-free devices for vaccine delivery. Founded in 2005 and headquartered in Golden, Colorado, PharmaJet's technology utilizes a narrow stream of fluid to deliver injections without the use of needles, thereby addressing issues such as needle-stick injuries, needle reuse, cross-contamination, and sharps waste disposal. The company offers its products under the Stratis and Tropis brands, which are designed to provide accurate and comfortable injections for various target tissues. By eliminating the risks associated with traditional needle-syringe delivery systems, PharmaJet aims to enhance safety and efficiency in immunization practices.

Otricath is a medical technology company focused on improving the delivery of cancer therapies, particularly for liver cancer. The company has developed a closed-loop catheter system that allows healthcare professionals to administer chemotherapy directly to solid tumors while minimizing systemic toxicity. This innovative platform features a three-part catheter designed to deliver anticancer agents in a sealed environment, ensuring enhanced control, predictability, and safety in treatment. By concentrating treatment directly at the tumor site, Otricath aims to optimize therapeutic benefits for patients undergoing cancer treatment.

Innoblative Designs, Inc. is a medical device company based in Chicago, Illinois, with an additional office in Mansfield, Massachusetts. Established in 2013, the company specializes in the development of innovative electrosurgical devices aimed at enhancing surgical procedures. One of its key products is Sira™, a Saline-assisted Intraoperative Radiofrequency Ablation device. This device utilizes bipolar current to create a controlled zone of ablation during surgery, facilitating the coagulation and ablation of soft tissue beds. Sira's unique design features a saline microinfusion system that ensures optimal contact with target tissue, allowing it to be seamlessly integrated with existing electrosurgical generators in operating rooms. This makes Sira an accessible and effective option for surgeons seeking to improve intraoperative ablation techniques.

Patientory Inc., established in 2015 and headquartered in Atlanta, Georgia, specializes in developing a personal healthcare solution named Patientory. This platform enables individuals to securely manage their medical records, monitor chronic illnesses, and access relevant health information. Simultaneously, it facilitates healthcare providers' connection with patients for support and care coordination. By empowering users to control their health data and incentivizing healthier lifestyles through personalized rewards, Patientory aims to streamline interactions between healthcare stakeholders and patients while reducing care costs.

Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing innovative venous access devices that utilize advanced hydrogel materials to significantly reduce thrombosis accumulation, a common complication in intravenous therapy. Their product line includes peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. By addressing critical issues such as occlusions and infections, Access Vascular aims to enhance clinical outcomes, lower healthcare costs, and improve patient experiences. The company's HydroPICC catheter exemplifies their commitment to advancing venous access technology, as it offers superior performance over existing solutions, thereby increasing catheter dwell time and minimizing associated complications.

M&S Biotics, LLC is a healthcare Internet of Things company based in Scranton, Pennsylvania, established in 2014. The company specializes in enhancing the efficiency, efficacy, and safety of surgical procedures through its Biotic Integration system. This innovative system employs radio frequency identification (RFID) technology and artificial intelligence to automate the counting of surgical items in real time, significantly improving operational workflows in the operating room. Additionally, M&S Biotics offers the Biotic Insight analytics platform, which provides hospitals and surgical facilities with valuable insights into instrument utilization. By streamlining surgical processes and reducing costs associated with inventory management, M&S Biotics aims to alleviate the financial pressures faced by healthcare institutions while improving patient care.

NovaGray is a biotechnology company focused on the development of advanced companion diagnostic tests designed to enhance radiation therapy planning. The company’s innovative biomarker-based tests evaluate patient sensitivity through a single blood sample, allowing healthcare practitioners to customize treatment doses and session sequences based on individual patient profiles. This personalized approach aims to improve patient outcomes while simultaneously reducing complications and overall treatment costs. By enabling physicians to tailor standard radiotherapy treatments to the specific sensitivities of patients, NovaGray seeks to significantly advance the efficacy of cancer care.

VADovations, Inc. is an Oklahoma City-based company focused on designing and manufacturing innovative healthcare equipment, particularly in the field of cardiac assistance. Founded in 2009, VADovations specializes in developing a miniature ventricular assist device, a mechanical blood pump that is smaller and lighter than existing options. This advanced device allows for less invasive surgical implantation, significantly reducing hospitalization time from three weeks to just four days. The technology is designed to provide circulatory support for patients with end-stage heart failure, utilizing percutaneous delivery and endovascular deployment methods. By minimizing the risks associated with traditional blood pumps, such as stroke, bleeding, thrombosis, and infection, VADovations aims to enhance the safety and effectiveness of cardiac procedures performed by cardiothoracic surgeons and interventional cardiologists.

2Morrow, Inc. is a digital health company based in Kirkland, Washington, that specializes in evidence-based behavioral change programs and applications. Founded in 2012, the company develops a range of products aimed at improving health and wellness. Its flagship programs include SmartQuit, a smoking cessation program grounded in acceptance commitment therapy; My Pocket Coach, which helps users set and achieve personal goals; and Healthy Habits, designed to cultivate positive habits and eliminate negative ones. 2Morrow distributes these programs through various channels, including employers, state health initiatives, wellness programs, and health plans. With a strong emphasis on research, the company has published multiple studies and participated in clinical trials, further establishing its role in the digital health arena. 2Morrow continues to innovate, with additional products in development targeting substance use and chronic conditions.

Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

VerteCore is a developer of an innovative orthopedic medical device aimed at relieving lower back pain. The company has created the VerteCore Lift, a patent-pending system that offers a non-surgical approach to spinal decompression. This device targets various sources of back pain, including compressed or bulging discs, sciatica, and functional scoliosis, using a dual support harness and a unique ratcheting mechanism for ease of use. By providing a convenient and mobile solution, VerteCore enables active individuals to find rapid relief from spinal discomfort without the need for hospitalization, medication, or surgical intervention.

Abreos Biosciences, Inc. is a biotechnology company that specializes in developing lateral flow assays to measure the activity of biologics. Founded in 2013 and headquartered in San Diego, California, the company offers a range of products including Veritope, a peptide-based detection reagent used for detecting counterfeit biologic drugs and providing dosing guidance for monoclonal antibody therapies from whole blood samples. Abreos also provides ligand binding assays aimed at biologic and biosimilar drug development, as well as massively multiplexed biomarker assays. Its C3-LFA lateral flow assay platform is utilized for the authentication of biologics, including BOTOX, and for endotoxin testing across various sectors such as pharmaceuticals, medical devices, and food safety. Additionally, the company has developed the MudPAQ sensor platform, which enables multiplexed protein detection and quantitation, facilitating proteomic studies related to cancer cells and biomarkers. Abreos maintains a laboratory in San Diego and an office in Marseille, France.

Nanowear, Inc. is a technology company specializing in textile-based nanosensor solutions for wireless and real-time electrophysiological monitoring. Founded in 2014 and headquartered in Brooklyn, New York, with a research and development facility in University Park, Pennsylvania, Nanowear develops innovative products such as SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, designed for the management of congestive heart failure. These garments collect multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, transmitting it to a web-based portal accessible by healthcare professionals via a mobile application. The company's proprietary technology serves various markets, including cardiac, neurological, industrial safety, government, sports medicine, and performance diagnostics, providing accurate, continuous, and cost-effective diagnostic data in an unobtrusive manner.

Centerline Biomedical, Inc. is a Cleveland, Ohio-based company founded in 2014 that specializes in developing advanced surgical navigation technologies. The company focuses on an Intra-Operative Positioning System, which utilizes non-x-ray based three-dimensional GPS technology to enhance the precision of endovascular procedures and minimize radiation exposure for both patients and medical staff. Centerline's innovative system aids surgeons in navigating complex three-dimensional vascular anatomy, thereby improving surgical outcomes in interventional vascular procedures. The technology is rooted in advancements made at the Cleveland Clinic, reflecting a commitment to enhancing the safety and effectiveness of minimally invasive surgeries.

EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.

PneuMotion is a manufacturer of advanced respiratory monitoring equipment focused on detecting opioid-induced ventilation impairment. The company specializes in continuous respiratory rate monitoring and obstructive apnea detection, providing healthcare facilities with an effective means to enhance patient safety, particularly in opioid administration contexts. PneuMotion's technology is designed for seamless integration into existing hospital networks, facilitating mobile respiratory monitoring and electronic health record (EHR) data collection. By utilizing ultra-low cost sensor technology, PneuMotion offers a cost-effective solution for improving patient outcomes and ensuring safety in clinical settings.